FDA Provided Guidance on AMO-02 Trial Design
The agency suggested key endpoints for a potential Phase 3 study of the drug for treating ACM.
Updated on Oct. 7, 2026 in Heart Disease
Live Poll
Should regulators expedite development paths for drugs treating rare, life-threatening conditions?
The FDA has provided non-binding guidance to AMO Pharma regarding the primary outcome measures for a future Phase 3 clinical trial of AMO-02. The agency recommended using an endpoint that tracks the effects on ICD therapies and sustained symptomatic VT events in patients with ACM.
Why it matters
Defining a clear development pathway is essential for AMO Pharma as it looks to address ACM, a rare and inherited cardiomyopathy. The guidance helps the company align its research goals with regulatory expectations for the eventual approval of the treatment.
The ongoing Phase 2 study for AMO-02 consists of 120 patients across 17 sites in Canada. While the FDA has provided non-binding feedback, primary data from the Phase 2 TaRGET trial are not expected until 2028.
The players
FDA
The Food and Drug Administration is the U.S. federal agency responsible for protecting public health through the regulation of medical products.
AMO Pharma
AMO Pharma is a London-based clinical-stage biopharmaceutical company focused on developing therapies for rare genetic diseases.
PHRI
The Population Health Research Institute is an international research organization that manages large-scale clinical trials.
The details
AMO Pharma, a clinical-stage biopharmaceutical company, requested the consultation to formalize the clinical strategy for treating ACM. PHRI is currently managing the randomized, double-blind, placebo-controlled Phase 2 trial to evaluate the drug's performance.
Timeline
October 7, 2026: The FDA provided advice on Phase 3 trial design.
2028: First data from the Phase 2 trial is expected.
Deeper Dive
This story follows the structural development pattern set by the TaRGET Phase 2 trial for rare cardiomyopathy research. The current FDA guidance marks a developmental progression in the ongoing TaRGET research program.
Patients with ACM currently face limited treatment options for this rare inherited heart condition. The progression of the AMO-02 trial provides a potential future pathway for managing symptomatic VT events through regulated clinical developments.
The takeaway
Advancing clinical trials for rare cardiomyopathies requires clear regulatory alignment early in the development cycle. Patients and providers should monitor the ongoing Phase 2 results as a key indicator for the viability of future treatment protocols.
What happens next
The first data from the Phase 2 TaRGET study are expected to be released in 2028.
Further reading
For more on the current landscape of cardiac research, visit the Heart Disease section.
More information
For more information on the development of these therapies, visit the AMO Pharma company website.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should regulators expedite development paths for drugs treating rare, life-threatening conditions?
